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Summal'y 
The class II major histocompatibility complex (MHC) molecules function in the presentation 
of processed peptides to helper T  cells.  As most mammalian  cells can endocytose and process 
foreign antigen,  the critical determinant  of an antigen-presenting  cell  is its ability to express 
class II MHC molecules. Expression of these molecules is usually restricted to cells of the immune 
system and dysregulated expression is hypothesized to contribute to the pathogenesis of a severe 
combined immunodeficiency syndrome and certain autoimmune diseases. Human complementary 
DNA clones encoding a newly identified, cysteine-rich transcription factor, NF-X1, which binds 
to the conserved X-box motif of class II MHC genes, were obtained,  and the primary amino 
acid sequence deduced.  The major open reading frame encodes a polypeptide of 1,104 amino 
acids with a symmetrical organization.  A central cysteine-rich portion encodes the DNA-binding 
domain,  and  is  subdivided  into  seven  repeated motifs.  This  motif is  similar  to  but  distinct 
from the LIM domain and the RING finger family, and is reminiscent of known metal-binding 
regions.  The unique arrangement  of cysteines indicates that the consensus sequence CX3CXL- 
XCGXI-sHXCX3CHXGXC represents a novel cysteine-rich  motif. Two lines of evidence indicate 
that the polypeptide encodes a potent and biologically relevant repressor of HLA-DKA trans- 
cription: (a) overexpression of NF-X1 from a retroviral construct strongly decreases transcription 
from the HLA-DRA promoter;  and (b) the NF-X1  transcript  is markedly induced late after 
induction with interferon 3/(IFN-'y), coinciding with postinduction attenuation of HLA-DRA 
transcription. The NF-X1 protein may therefore play an important role in regulating the duration 
of an inflammatory response by limiting the period in which class II MHC molecules are induced 
by IFN-y. 
T 
he class II region of the human MHC encodes three het- 
erodimeric molecules: HLA-DK, -DQ, and -DP com- 
posed of ot and B chain polypeptides with an approximate 
molecular weight of 60,000  (1).  Peptides derived from ex- 
tracellular  antigens are recognized by helper T  cells in the 
context of these molecules (2). These molecules are expressed 
constitutively on professional APCs such as macrophages,  den- 
dritic cells, and B cells and their biosynthesis is inducible on 
other cells upon binding of certain lymphokines such as IFN-'y, 
IL-4, and TNF-ot to their respective receptors (3, 4). Class 
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II MHC genes are inactive in plasma cells,  and cell fusion 
experiments indicate that  a dominant  repressor protein ac- 
tively inhibits transcription of these genes (5). These highly 
polymorphic molecules determine the ability of an individual 
to respond to a given antigen, and the molecular basis of this 
lies in the differential capacity of allelic forms of these mole- 
cules to bind particular  peptides (6). Because of the central 
role these molecules play in the initiation of the immune re- 
sponse, considerable effort is focused on elucidating the mech- 
anisms governing the proper tissue-specific and developmental 
regulation  of the class  II MHC genes  (7,  8). 
Expression of the class II MHC genes is controlled pri- 
marily at the transcriptional  level (9,  10).  Systematic dele- 
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and  murine  class  II genes  have identified  two  highly con- 
served cis-acting elements called the X  and Y boxes that bind 
several transcription factors that participate in the regulation 
of these genes (11-14). These regions are occupied by DNA- 
binding  proteins  in  class  II-positive  cells but  not  in  class 
II-negative or in certain Bare Lymphocyte Syndrome cell lines 
(15,  16). The X-box is further subdivided into an upstream 
X1  box  (5'CCTAGCAACAGATG3')  and  an  X2  box 
(5'CGTCATCY) located immediately 3' of the X1 box (5). 
A  family of genes encoding X1 box binding  proteins have 
been cloned (RFX1-5) and at least one of these, RFX5,  ap- 
pears to be required for class II MHC gene transcription (17, 
18).  At least  three factors (hXBP1,  hXBP2,  and c-jun)  can 
interact directly with the X2 box, with the product of the 
c-Jos proto-oncogene being a likely partner (19-23).  The Y 
box is in fact an inverted CCAAT box which can bind a mul- 
tiplicity of factors. Two factors, YB-1 and NF-Y, have been 
implicated in class II MHC  gene regulation.  YB-1 appears 
to encode a potent repressor of IFN-3'-induced class II gene 
expression, whereas the heterodimeric NF-Y encodes an ac- 
tivator (24-26).  The Y-box may therefore act as a bifunc- 
tional cis-element,  binding both an  activator and repressor 
of class  II  MHC  gene expression. 
Recently, a novel factor (CIITA) required for both consti- 
tutive and IFN-y-mediated expression of all of the class II 
MCH genes, has been isolated by complementation cloning 
using a mutant B-lymphoblastoid cell line (27, 28). This factor 
does not appear to interact directly with the class II MHC 
proximal promoter, but CIITA transactivation  is mediated 
by the proximal promoter (presumably via protein-protein 
interactions  between  CIITA  and  other  class  II  promoter 
binding proteins).  In this report, we describe a unique X1 
box binding protein, NF-X1, which represses class II MHC 
gene expression and provides an initial structure/function anal- 
ysis of the protein. 
Materials  and Methods 
Cell Lines.  P,  aji and Jijoye cells are MHC class II-positive EBV- 
transformed human B lymphoblastoid cell lines. Jurkat is a class 
II-negative human T cell line. All three lymphoid cell lines were 
maintained in RPMI-1640 supplemented with 10% heat-inactivated 
FCS, 20 mM Hepes, penicillin/streptomycin, 2 mM glutamine, and 
1 mM sodium pyruvate. HeLa cells were maintained in DMEM 
media.  Transcription of the HLA-DRA gene and cell surface ex- 
pression of the HLA-DR molecule is inducible by addition ofrIFN-3~ 
to these cells at a concentration of 100 U/m1 for 24-48 h. 
cDNA Cloning and DNA Sequence Analysis.  Infection, plating, 
fusion protein induction, and nitrocellulose filter lifts  were per- 
formed as described in (29).  The oligonucleotides used to probe 
the immobilized recombinant fusion proteins were: HLA-DQB X 
(AAAATCTGCCCAGAGACAGATGAGGTCCTT)  and  HLA- 
DPB  X  (ACTTTCTGCCTAGTGAGCAATGACTCATAC).  A 
HLA-DRA S box probe (TGTGTCCTGGACCCTTTGCAAGA) 
was also included in the screens. Double-stranded oligonucleotides 
were endlabeled with y-[32]ATP using T4 polynucleotide kinase 
and subsequently concatenated with DNA ligase. Ligation efficiency 
was monitored by gel electrophoresis. Oligonucleotides were syn- 
thesized on a DNA synthesizer (model 391; Applied Biosystems, 
Inc., Foster City, CA). Potential positive clones were subjected to 
secondary and tertiary screens. Insert cDNAs were then subcloned 
into pBluescript cloning/sequencing vectors, and restriction maps 
were generated. Bidirectional exonuclease deletions of the full-length 
clone-16 insert were generated and both strands  were sequenced 
by the dideoxy method. A few regions that were between deletion 
points were sequenced  using complementary oligonucleotides. 
Southern and Northern  Blot Analysis.  High molecular weight 
DNA was isolated  from the indicated cell lines as previously de- 
scribed (30). After restriction digestion with the indicated enzymes, 
DNA was transferred to Gene Screen Plus hybridization membranes 
and  prehybridized,  hybridized,  and  washed  according  to  the 
manufacturer's guidelines  (DuPont-NEN, Boston, MA). The hy- 
bridization probe was the EcoRI insert from the clone-16 bacterio- 
phage. Northern blotting was also performed using the same mem- 
branes according to manufacturer's protocols using the same DNA 
probe. The HLA-DRA-specific probe is as previously described (8). 
RNA was isolated using the guanidium thiocyanate procedure (31). 
20/zg total cellular  RNA was separated after denaturation on an 
agarose/formaldehyde gel, transferred to hybridization membrane, 
and probed with  the NF-X1  cDNA.  The Northern blots were 
washed at high stringency and subjected  to autoradiography. 
RT-PCR and RNase Protection Analysis.  RT-PCR was performed 
on samples of HeLa, Jurkat, and Jijoye total RNA isolated using 
the Guanidium isothiocyanate/cesium chloride (GIT/CsC1) proce- 
dure. cDNA synthesis  was performed with 10/xg total RNA in 
50 mM Tris-HC1, pH 8.3, 10 mM MgClz, 100 mM KCI, 10 mM 
dithiothreitol, and 500/zmol of each dNTP, 25 pmol 3' PCR primer, 
7 U AMV-RT, and 1/~1 RNAsin (Promega, Madison,  WI). The 
total reaction volume was  11 #1. After incubation at 37~  for 1 
h, 5/xl cDNA reaction mixture was used for amplification via PCR 
using  internal  NF-X1  antiparallel  oligonucleotide primers.  For 
RNase protection analysis, an antisense  probe for the human 3'- 
actin gene was synthesized by linearizing the plasmid SP6-3-actin 
(32) with Hinfll (New England Biolabs, Inc., Beverly, MA) fol- 
lowed  by  transcription  in  vitro  using  SP6  RNA  polymerase 
(GIBCO-BRL, Gaithersburg, MD) and [32p]CTP (800 Ci/mmol; 
DuPont-NEN). 3.2 kb of the NF-X1  cDNA was subcloned into 
pBluescript  to generate pBSclone-16. The antisense probe for NF- 
X1 was prepared by first linearizing the pBSclone-16 plasmid with 
Aatll and transcribed using T7 RNA polymerase.  25 #g of each 
total RNA preparation was lypholized and hybridized at 45~  with 
500,000 cpm of each labeled riboprobe. Hybrids were digested for 
30 rain at 30~  with RNase One (Promega) as recommended by 
the manufacturer. 
Recombinant Protein Production and Electropkoretic Mobility Shift 
Assay.  Recombinant proteins were produced essentially as previ- 
ously described in (33). NF-X1 was produced either as a lysogen 
as described in the text, or from the T7 expression  system (34). 
Protein was partially purified as previously described (35) and dia- 
lyzed against 50 mM Tris, pH 7.9, 0.5 M NaCI,  10%  glycerol, 
and 1 mM PMSF. Gel mobility shift assays were performed by in- 
cubating bacterially produced NF-X1  with endlabeled  probes for 
30 min at room temperature in binding buffer consisting of 13 mM 
Tris, pH 7.9, 60 mM KC1, 12.5 mM NaC1,  12%  glycerol,  and 
75 #g/ml poly:dldC. The binding reactions were then resolved on 
low ionic strength 5% nondenaturing polyacrylamide gels and elec- 
trophoresed at  10 V/cm at room temperature (36). 
Construction of NF-XI  Truncation Vectors, Filter Lift DNA-binding 
Analysis.  Truncated NF-X1 cDNA fragments were first subcloned 
into appropriate pRSET vectors (Invitrogen, San Diego, CA) to 
place a methionine residue  NH2-terminal and in-frame with the 
fragment. NF-X1.A was subcloned into the pRSET.C vector with 
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pRSET.B with an NHz-terminal BamHI site, NF-X1.F was sub- 
cloned into pRSET.C with an NH2-terminal SspI site, and NF- 
X1.G was subcloned into pRSET.A with an NH2-terminal PstI 
site. PCR was used to amplify the resulting expression  casettes and 
to insert terminal EcoRI recognition sites where appropriate. These 
products were purified by binding to glass beads and ligated to 
Xgtll bacteriophage arms (Stratagene, La  Jolla, CA). The ligation 
reaction was then packaged (Gigapack  Gold; Stratagene) and plated 
on Y1090 bacteria (37). Individual plaques were purified and as- 
sessed for insert orientation and binding ability in filter binding 
assays. After plaque lifting, filters  were subjected  to stepwise  denatu- 
ration-renaturation  and screened with multimerized radiolabeled 
probes as previously described (38). The binding buffer consisted 
of 12 mM Tris pH 7.9, 40 mM KC1, 0.12 mM EDTA, 30/zM 
ZnSO4, and 400 #M/5-MER. BSA (fraction V) was used in place 
of  dried nonfat milk as a blocking agent. The binding and washing 
reactions were performed at 4~  Autoradiographs were exposed 
overnight with intensifying screens. 
Transient Transfections and CAT Assays.  Transfections  were ei- 
ther performed using the DEAE dextran method, as previously 
described (8), or using the lipofectamine reagent (GIBCO-BRL) 
according to the manufacturer's specifications.  Typical  transfections 
included varying amounts of effector plasmid (1-15/~g), 1-5/~g 
of reporter construct, and 5 #g of thymidine kinase/human growth 
hormone (tkHGH) transfection control plasmid. 48 h after trans- 
fection, cells were harvested by centrifugation, washed twice, and 
extracts prepared by multiple cycles  of freeze/thaw. Chloramphen- 
icol transferase (CAT) assays  were performed as previously  described 
(8, 22, 23). Each transfection experiment was performed five  times 
to calculate standard errors. 
Results 
Isolation of cDNA  Clones Encoding  NF-X1.  A number of 
overlapping complementary DNA clones encoding a newly 
identified human X1 box binding protein have been isolated 
by screening a Raji cell Xgt11 expression library with a mix- 
ture of multimerized, radiolabeled, double-stranded oligo- 
nucleotides spanning the X boxes (and surrounding nucleo- 
tides) of the human class II MHC genes HLA-DQB and -DPB 
(38). Through restriction mapping and dideoxy sequence anal- 
ysis, six overlapping cDNAs have been found to encode the 
same DNA-binding protein, designated NF-X1. The restric- 
tion map and the sizes of the overlapping clones are shown 
CLONE- 16 
in Fig. 1. One of these clones: clone-16, encodes a full-length 
(or nearly full-length) copy of the NF-X1 mRNA as esti- 
mated by Northern blot analysis (see Fig.  6,  and data not 
shown). The complete nucleotide sequence of the clone-16 
bacteriophage insert has been determined by (a) sequencing 
exonuclease generated truncations of the insert subcloned into 
the pBluescript vector (Stratagene),  and (b) using oligonu- 
cleotide primers complementary to various locations within 
the cDNA to derive additional sequence information. Each 
portion of the cDNA has been sequenced multiple times and 
on both strands. Clone-16 extends 4,053 nucleotides beyond 
a short 5' untranslated region, including a 3,312-base largest 
open reading frame (ORF) 1, and 741 bases 3' of the termi- 
nation codon. This clone contains the entire 3' untranslated 
region and contains a Poly(A) tail.  We have identified two 
other types of clones that contain shorter 3'  untranslated 
regions followed by long Poly(A) tails which presumably re- 
sult from distinct Poly(A) addition sites. The complete nucleo- 
tide sequence of an mRNA containing the first polyadenyla- 
tion site is shown in Fig.  2 A. 
Primary Structure Analysis of  NF-X1.  The single large ORF 
encodes  a polypeptide of 1,104 amino acids. The complete 
deduced amino acid sequence of this ORF is shown in Fig. 
2 A. The estimated molecular weight of the polypeptide is 
121,440. Primary structural analysis of NF-X1 indicates that 
the protein has a general symmetrical organization (Fig.  2 
B).  The polypeptide has four potential sites for N-linked 
glycosylation and 52 potential cAMP, CK2, and PKC phos- 
phorylation and myristylation sites scattered throughout the 
polypeptide (positions are available upon request). This high 
density of potential posttranslational modification sites sug- 
gests that these modifications may play an important role 
in regulating the function of NF-X1. A large central region 
of 550 residues is rich in cysteine (17%).  Hydropathy anal- 
ysis indicates that the polypeptide is generally hydrophobic 
with the exception of the central domain (residues  430  to 
680)  which is less hydrophobic (Fig.  2 C).  Seven repeated 
domains with the general consensus sequence  CxxxCxLx- 
CGxl-sHxCxxxCHxGxC  are  found  in  this  region  and 
1  Abbreviations used in this paper: ORF, open reading frame. 
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Figure  1.  Overlapping X-gt11 
cDNA clones  encoding  NF-X1, the 
restriction map of clone-16, and the 
NF-X1 mRNA structure. Six over- 
lapping cDNA inserts of bacterio- 
phage clones encoding  portions of 
a newly  identified  MHC class  II X1- 
box binding protein, NFoX1, are 
shown.  Bacteriophage clone-16, 
contains an insert of 4,053 nucleo- 
tides which encompasses  all of the 
other cDNA inserts. A restriction 
map of the clone-16 EcoRI  cDNA 
insert is shown. The mRNA con- 
tains a long ORF frame of 1,104 
amino acids  with a short 5' untrans- 
lated region and a 741-base 3'-UT. 
Clone-16 contains a Poly(A) tail. 
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AT  GGAATT  CAGCAGCATCTGTATTGAATTT 
Met  GluPhegerSerIleCys  I  leGluPhe 
CTGTTCATCAGCATAGTTATCATCCGTCAG 
Leu~heIleSerlleValIleIleArgGin 
AGAGTCAAGAAAGCACAGAGTCTTGCTGAG 
ArqValLysLysAlaGlnSerLeuAlaGlu 
AAACCCAAAAAAGCAACACAGTTTGTATAC 
LysProLysLysAlaThrGln~heValTyr 
ACTCTTCAGAGGCATCCTCTAGAAAAGGAG 
ThrLeuGlnArgHisProLe~GluLysGlu 
~CGACAT~CAAACGCAGGACACAGAAACA 
ThrAspIleGlnThrGlnAspThrGluThr 
GTACGGAGGCAGGATCCTCAAGTAGTATCT 
ValArqArgGlnAspProGlnValValSer 
AAAAGTACCTTG~ACAGGAGGCGCCTC  CG CCATCCCGTGCCGCAGAAC  CTAGATCGAGC 
LysSe  rTh  rLeuArgGlnGluAlaP  top  ro P  rose  rArgAlaAlaGluP  roar  gSerSe  r 
GAAGGCAAACCTAAGAGTCAGCAGACGTCT TTCCAGTCCTCTCCTTGTAATAAATCGCCC 
GIuG  lyLys~  roLysSerG  InGlnThrger ~h~G  h3Ser  ~e  rP  roCysAsnLysSer~ro 
CAGACCTCAGATACAGCTGGATTAGAGAGC T  CGACCAGATC  AGAGAGTGGGACAGACCTC 
GlnThr  Se  rAspTh  rAlaG  I  yLeuGluSe  r Se  rTh  rArgSe  rG  fuse  rG  i  yThrAspLeu 
AGCTATGGTAGAGG  ACCAAAAGTCAAGGAG AAACTCAAATGTGAATGGAGT  AACCGAACA 
$erTyrGl  yArgGlyP  roLysVa  iLysGlu LysLeuLysCysG  luT  rpge  rAsnAr  gTh  r 
TATTGGATGGGTATGGAGCCAGACCAAATG AGC  AG  AG  AAq  ATAC  r162  AG  AAAAGGCCTC 
T  y  rT  r~Me  ~  G1  yMet  G  lu2  r  oAspG  luMe~ Se  rArgGluAspTh  rHisArg  LysG  l~Leu 
ACATC~GCCCCATTCCAAAGTGATGACCTC AATGAAAGACCAGCAA~TCTACCTGTGAC  AGTGAGAACTTC~CAGTCATCAACAAGTCT 
ThrTrpAlaPro~heGlnSerAspAspLeu AsnGluArgProAlaLysSerThrCysAsp $erGluAsnLeuAlaValIleAsnLysSer 
CCTTTCTCCCGAGGCAAACAGAACCATGTG CTAAAGAATGTGGAAACGCACACAGGTTCT CTAATTGAACAACTAACAACAGAAAAATAC 
ProPheSerArgGlyLysGlnAsnHisVal LeuiysAsnValGluThrHisThrGlyger LeulleGluGlnLeuThrThrGluLysTyr 
TGTA  CCTGTCACCTTT CCAC~CCTTATGATGAAATCTCTG 
CysTh  EVa  iHlsM  isLe~P  roVa  IThrPhe p  tog  lyArqSer  LeuMetMet  LySSe  r  Leu 
AAGAGCCATGG~TCAACCTTGG  CAGAAATT~GCACCATATC 
LysSe  z141sG  IyLeuG  inAsnG  InP  rot  ~  G  in  5ys  LeuArg~snG  luLy  s  Ri~41s  [le 
AGAGAGCATAGTCC~AGT  GAGAAG GAAGTTGTGGGTGCAGATCC  CAGGGGAGCA 
ArgGluHisgerP  rose  rG  luSerGluLys GluVa  iVa  iGlyAlaAspP  r  oArqGlyAla 
ACTCC  AAA CCGGAGATGCTGGACCCGAA  GTACCAAACCTGTC~TCCACCCTG 
Th  rp  ro  Lys~  roGluMet  LeuAspP  roLys Va  ip  roAsnLeuT  rpGlyPhe  Se  rThrLeu 
CCTGGGAAGTGG  AGGGGGC  CAGGC  C  ACG  AC CAGGCAGAAATCCACC  AAAAC  AGGAGGCC  C 
~  roGlyLysT  rpArgG  ly~  tog  i  y~isAsp GlnAlaGlul  le/4isG  inAsnArgAzgAla 
TCCAGGAGGGTTGACCAAGAG~AT~AC  T 
Se  rArgArgVa  IAspG  inG  luLysCysThr 
GAGT  GCATGGT  GTGCT  GTGAATTGGT~C  GT 
GluCysMetValCysCysGiuLeuValAIg 
GTCACGGCCCCAGTGTGGAGTTGTCAGAGC T~TTACCATGTGTTTCATTTGAACTGCATA AAGAAATGGGCAAGGTCTCCAGCATCTCAA GCAGATGGCC~GGTTGGAGGTGCCCT 
ValThrAlaProValTrpSerCysGlnSer CysTyrHisValPheHisLeuAsnCysIle LysLysTrpAlaArggerProAlaSerGln AlaAspGlyGlnserGlyTrpArgCysPro 
AATACCTTCTCTTGTTTCTGTGGCAAGGTA AAGAATCCTGAGTGGAGCAGAAATGAAA  TT~CACA~AGCTC'C~TCA~C~ACAAAG  AAACAGCCTC~CAC~AC~C~CCACAT~CC 
AsnThrPheSerCysPheCysGIyLysVal LysAsn~roGluTrpSe~ArgAsnGlu~le ProHis~erCysGlyGluValCysArgLys LysGinPrcGIyGlnAspCysProHlsger 
~CACCCTC~yC~CC~TATGgCAAAAAC~  ~CT~A~TC~GAC~AACCA~nCaC~CS~T~ 
ProProCysProAlaPheMes  CysGluCysGlyArgThrArgHisThrVal 
~GTCACT~CCA~CCT~GCCAGATCAT  ~ T~GAACCACZTAT~CTAT~G~GC~GCAL~] 
GlyGlyGlnCysGlnProCysGlnIleIle LeuAsnGlnValCysTyrCysGlySerThr 
~'~.,CCCT~ACCaTACaT~TTC~C~ACTGT~C 
CysGlyAsn~isThrCysSerGl~ValCys 
~ACCCTCTCCCTTCA~T~AAAACTCT~C 
AspProValProSerCysGlyLysValCys 
ACAAAGGAGCTTCCATGTACCAGTCTCAAA 
ThrLysGluLe~ProCysThrSerLeuLys 
IA~GAAACTCCZTm~TGCCCT'CATA~TnT 
ArgLysLeuAr~CysGlyLeuHisArgCys 
GAATGTACCCAAACCTGCGCTAGAGTCCAT 
GiuCysThrGlnThrCysAlaArgValHis 
K'?G~T~CAT~TC-C~T~C~nAT~ACCC~6C 
LeuValAsp[leSerCysGiyLetlProCys 
~--A~ZT~C~C-CCC~TSCCA~CTC~CCC 
CysMe[AlaProCysHisThrgerSerPro 
C~CCCTCACCCCTCCC~C~AT<CCC~C~C 
HisProGlnProCysGlnGlnCysProArg 
~CAA~CUeC~GCCTTCTCCT~CCT~AGAT 
GlyLysProLeugroCysGlySerLeuAsp 
AGTGAAGATGCTACATTTATGTGTGACAAG 
SerGluAspAlaThrPheMetCysAspLys 
GAAGAACC~TCTCATCCT~AnAC~nCCAG 
GluGluProCysHisAr~GlyAsnCysGl~ 
GAGTGTGACCATCCAGTATATCATTCTTGT 
GluCysAspHisProValTyrHisSecCys 
~GT~CC~C~C~ACCATC~C~AT~CACAAA 
SerAlaThrLeuProCysGlyMe~HisLys 
~C~CCmCT~ACTGCT~C~AAC~5~GGTA 
CysP  roVaiThrAlaCysLysAlaLysVal 
CC~TGTGGTFAGGC~G~C~AC~CCAC.'~T TC~AACCCATG~AC~TA~AAC~CT 
ArgCysGiyGlnAlaValSerValHisCys SerAsnProCysGluAsnIleLeuAsnCys 
TCCCGAGATGTGTTATGTGGAACCGATGTA GGAAAGTC~  ,,ATC~TT~C~A~@~CAGC 
SerArgAspValLeuCysGlyThrAspVal GlyLysSerAsDGlyPheGlyAspPheger 
CTCCCCC~CC~CC~CC~C~T~CCCCCTCY 
Leu~roGlnLeuValArqCysCysProCys 
~CAT~CATACCT~TCAAAACC~CT~CCAT 
PhelleHisThrCysGluLysLeuCysHis 
CGGTGTAACAAGAAACGGTTGTGTGGACGG 
ArqCysAsnLysLysArgLeuCysGlyArg 
aC~TGr-cncaacuna(,,~,  ~aTCAAT~A 
ThrCysTrpGlnAlagerPheAspGluieu 
CATAGTGAGGAGAAGTGTCCCCCTTGCACT 
HisSerGluGluLysCysProProCysThr 
~GTCACA~AC~C~CTCACAAA~CA~TCT 
CysGlnArgLeuCysHisLysGlyGiuCys 
cACC~aC~-CT~a',{, k~ACGAAGAAAA 
GluLeuGinCysGluCysGlyArgArgLys 
:~.~AAACTCCTCTCAGCCAATTGCTAGAA 
GiyGlnThrProLeuSerGlnLeu/~uGlu 
CA~AnA~U.~C~ACC~nTC~C~VCCACA 
GluGiyAspCysGlyProValSerArgThr 
CATAAATGTAATGAGATATGCTG~,TGG~T 
HisLysCysAsnGlu~leCysCysValAsp 
~CCTCCCATT~m~. ~CATCAGTGATTTAC 
ThrCysHisCysGlyAlaSerValIleTyr 
TTCCTAACTCAGAAGTGGTGCATGGGCAAG 
PheLeuThrGlnLysTEpCysMes 
c~.~.t,t(~AT~AC~CCTC~AAC~C~C~I~GC 
LeuValAspGlugroCysLysGlnProCys 
GAGATGGTGATTTCCTCTGAAGCATCTAGT 
GltLMe~ValIi~CysgerGluAlagerger 
GCCT  GTCAGAATGTTT  CTGCACATGT~CC  r 
AlaCysGlnAsnVa  1  Se  rAlaHisVa  IP  ro 
CysAsnLeuLeuCy  sHisP  tog  lyP  r~ys 
C.'~.TCACI'nCC'A  ,C'C,~GCTCACP  '~  ~  [  4  ~"  a  ,I 
G  lyG  inHisG  inCysAlaG  I  uLeuCFsHis 
~  C,~ A~  AC,  AC  A~CT  CVC  A  A  CC,  ACTTC~Aa 
Cy  sLeuLysTh  rCysG  lyLysAspLeuLys 
CTTC4]AAGTAGTAGTCGGAAAACATGC~ 
LeuGI  ySe  rSe  r  Se  rat  gLysThrCysMet 
~c  net  T  AT  T~CC~C~  AC.  AT~  ,~  i  ~'CTTTCAG  A 
SerVa  IIleSerCysArgCysSerPheArq 
~  ~  9c  Ac.c  ~  c  ~  n  c.~c~  Cc~  T~  C  ~  ~TT  C~C~n-  fl 
LysGIuHisLysCySP  roLeuZleCysGly 
C  CTCCAGTTCC  C  TST  GGT  ACTAGGCCCCCT 
p  roProVa  iPrcCysGlyThrArgP  tOP  ro 
C  ATG  AGTTTCGGAGC  AACATC  CCCTGT~ 
HisGluPheAr  gSe  rAsn  I  leP  roCysHis 
~  C  TA  CC  C  CC  AC,  ~  C~TC  AC~  C,  TC~,TC  ACC  C~ 
Th  rThrP  roArgAlaAspC  y  sGlyHisP  ro 
ACTT  AT  CAAAGAAT  AGCTGC  AATCTCCATG 
ThrTyrG  l~Args  leAlaAla  I  lege~Met 
GCCTCT  ~AGAT  ~AC  AG  ACATGCAGCTTGGA C~TTCAGTGGAGATCAGCAAGTTAATTACC 
AlaSe  rLys  I  leThrAspMe~G  ~nLeuGl  F GlySerVa  lGlullege  rLysLeus 
AGTGAGGATTCTG  ATCCTTTCAATATACGT TCTTCAGGGTCAAAATTCACTGAT  ~GTT~G 
Se  rGl~Aspge  rAspP  roPheAsnIleAr~  SerSerGlySerLysPnegerAspSerieu 
AGTAAGAAAAGCCACAGCTTCCCTCCCATG AACAGAGACCACCGCCGGATCATCCATGAC 
~e  rLysLys  Se  rHisSe  rPheP  roP  roMet AsnArgAspHisArgArgIle  I  leHisAsp 
TGTCCTCCTACCACGCTGACAGGTGTGCTT G  AAAGGGAAAT  G  CAC~C  ACGGC  CT  C  CACC  A 
CysP  toP  roThrThr  LeuThrGlyVa  iieu GluArgGiuMet  GlnAlaArgP  top  roP  ro 
IACGTCCAGGACT  AAGAAGAT  CATGATGCA CTTAGATAAAAG  AATG  ATTAGGTAT  AGT  GG 
AspVa  IG  inAs~, 
.~AAAAGGAAGTTCATCAACCCAGGCTGGAG TGTGATGAGGAGTGTTCAGCCTTGCAAAGG AA~AAGAGATTAGCAGAGGCAT-  "~CATATC 
LysLysGluVaIHisGlnA~aArgLeuGlu CysAspGluGluCysSerAlaLeuGloArg LysLysArgLeuAlaGluAlaPheHisZl~ 
~AAGAAGATGCCAGGAAGGACTT~AAGTTT GTCAGTGACGTTGAGAAGGAAATCGAAACC CTCGTGGAGGCCGTGAAT~AGGGAAAGAAT 
LysGluAspAlaArgLysAspSeuLTsPne ValgerAspValGluLysGluMetGluThr LeuValGluAlaValAsnLysGIyiysAs. 
TTGGCCCAAGTTTATGGCCTGGAGAGCGTG AGCTATGACAGTGAACCGAAGCGCAATGTG GTGGTCACTGCCATCAGGGGGAAGTCCGTT 
LeuAlaGlnValTyrGlyLeuGluSerVal SerTyrAspSerGlu~roLysArgAsnVal VaiValThrAlafleArgGiyLysgerVal 
CCGATTCCTCATCACAGACATCAGTCAGAC AAGAATCCTGGGAGCAGTAATTTACAGAAA ATAACCAAGGAGCCAATAATTGACTATTTT 
~roIleProHisHisArqHisGlns  LysAsrtProGlySergerAsnLeuGlnLys IleThrLysG1uPro[les 
AGACTTATTTGCCAGCAGATAAATCATGCC CGTTCCCCTCTC~TCACAGTC  TCACATACTGTCTTGTACTGACACATCCAA 
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Figure  2.  Deduced  amino acid sequence and primary structural analysis of the NF-X1 polypeptide. (A) The complete deduced amino acid sequence 
of the largest ORF of the NF-X1 mRNA is shown from the first in-frame methionine to the most ORF-proximat polyadenylation site. No other 
significant ORFs are detected in either strand, and in vitro transcription/translation of NF-X1 cDNA fragments produces polypeptides of molecular 
weights in agreement with this ORF. Two additional polyadenylation sites are also observed in additional clones (data not shown). (B) Primary structure 
analysis of NF-XI. The entire amino acid sequence was subdivided into 22 fragments of 50 residues (with the final fragment containing 54 residues) 
and analyzed using the Gene Works software program (Intelligenetics, Mountain View, CA). Note the general symmetrical organization  of the protein, 
with a 550-residue central cysteine-rich domain. Proline, serine, and glutamine-rich regions are also indicated, as are two acidic regions found at the 
NH2 and COOH termini. Seven repeats of approximately 40 residues in length are indicated within the cysteine-rich domain. (C) Hydropathy plot 
for the deduced amino acid sequence of NF-X1 using the algorithm of Kyte and Doolittle  (57). (D) Amino acid homology alignment of the seven 
repeated domains within the cysteine-rich region. The repeat motif was detected by screening for internal homology using the FASTP program and 
the Gene Works software. The consensus sequence was derived by aligning the repeat motifs. The numbers to the left of the polypeptides indicate 
the amino acid positions included in each repeat, and the numbers below the consensus indicate the number of repeats that contain the consensus 
amino acid. These sequence data are available from EMBL/GenBank/DDBJ under accession number x79874. 
these repeats are aligned in Fig.  2 D.  The repeated domains 
are roughly 40 residues in length.  The homology is greatest 
in the central portion of the repeat and decreases away from 
the center. However, several cysteine residues  within the repeats 
appear to be conserved regardless of their distance from the 
central homologous region. It is possible that these conserved 
cysteines serve as a framework for the structure of the repeating 
domain via disulfide linkages,  metal complexes,  or an alter- 
native  mechanism. 
The existence  of a cysteine-rich  domain raises  the possi- 
bility that this region might mediate sequence-specific binding 
via the formation of zinc finger(s).  However,  an exhaustive 
analysis  for prototypical  zinc-finger  motifs  does  not reveal 
any typical zinc finger motifs of the C2C2 or C2H2 types. 
Although  several  cysteine and histidine  residues do exist  in 
the NF-X1 repeats, the distances between them and in potential 
linking regions are nonstandard (39).  The repeated motif is 
itself most  similar  to but  distinct  from two previously de- 
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scribed families of metal binding proteins, the LIM domain 
and the RING finger families, and is therefore likely to rep- 
resent a novel metal binding domain (40,  41). The motif is 
highly significant since only seven proteins in the protein data- 
base contain stretches that are similar to the described motif, 
with the probability of detection being •1.5  x  10 -5.  All 
of the proteins that contain related motifs (e.g. RAG-l, Sac- 
charomyces cervisiae RAD18, herpes simplex Iell0, the ret on- 
cogene, the Caenorhabditus elegans developmental gene lin-11, 
and the insulin gene enhancer binding protein lsl-1) are thought 
to interact with DNA, although they are involved in the dis- 
tinct enzymatic processes of recombination, repair, and tran- 
scriptional regulation. Further investigation is required to de- 
termine what sort of structures form in this region and how 
they might mediate sequence-specific binding. 
The NF-X1 polypeptide contains several other features that 
are characteristic of transcription factors. Two acidic regions 
(between  residues  200-300  and  900-1000)  surround  the 
cysteine-rich domain. Three regions rich in proline (>20%) 
and two regions rich in glutamine (27%) are located within 
the cysteine-rich domain. Two serine-rich regions (>30%) 
are located 100 residues from each terminus, and two proline- 
rich (>20%) segments are found at the termini of the poly- 
peptide.  Investigations are in progress  to determine what 
regions of NF-X1  mediate its regulatory function. 
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Genomic Organization and Transcription of the NF-X1 Gene 
(42).  Southern  blot  analysis  of  human  genomic  DNA 
digested with multiple restriction enzymes (using the clone- 
16 cDNA insert as a probe) reveals multiple bands ranging 
in size from "~4 to >23 kb in length (Fig. 3 A). As the sum 
of these fragments greatly exceeds the total length of the NF- 
X1 mRNA, we conclude that the NF-X1 gene is interrupted 
by introns of considerable size or that a related gene or genes 
(or pseudogenes) exists within the human genome. Southern 
blot analysis of genomic DNA isolated from mouse, Dro- 
sophila, and yeast cells detects homologous sequences in each 
organism and indicates that the NF-X1  gene (or a related 
gene) is evolutionarily conserved (data not shown). Northern 
blot analysis of total RNA isolated from B and T cell lines 
detects an mRNA of '-4 kb in size which is expressed at 
very low levels (data not shown). Since the NF-X1 mRNA 
is present in low abundance, both an RT-PCR and an RNase 
protection assay have been used for its detection and quanti- 
ration, cDNA synthesized from total RNA extracted from 
the class II-positive B lymphoblastoid cell line Jijoye, and 
the class II-negative cell lines Jurkat  (T cell) and RJ2.2.5 
(mutant B-LCL), has been used as substrates for PCR using 
two antiparallel oligonucleotides derived from the NF-X1 
cDNA sequence. This nonquantitative RT-PCR detects NF- 
X1 mRNA in each cell line, regardless of class II phenotype (Fig.  3 B). A larger panel of RNAs extracted from several 
class II-positive and -negative cell lines has also been ana- 
lyzed for the presence  of NF-X1 mRNA using a sensitive 
and quantitative RNase protection assay (Fig. 3 C). These 
analyses demonstrate that the NF-X1 mRNA is ubiquitously 
expressed  in all cell lines  tested and is present at an abun- 
dance "~,50-fold lower than an internal "r-actin  control. 
NF-X1 Encodes a Promiscuous X1 Box Binding Protein.  Sec- 
ondary and tertiary screens of bacteriophage clones isolated 
in this screening included an initial assessment  of sequence 
specificity of encoded DNA-binding proteins by incubation 
of sections of nitrocellulose filter "lifts" with multiple radio- 
labeled recognition site probes. These analyses indicated that 
the NF-X1 protein interacts with both the DQB and DPB 
extended X box probes but not with the HLA-DRA S-box 
recognition site (data not shown). To allow further analysis 
of  binding specificity,  bacteriophage lysogens were constructed 
from the initial clone-16 bacteriophage using the method of 
Singh et al. (33). The binding specificity of isolated NF-X1 
fusion  protein  induced  after  1  h  incubation  in  10  mM 
isoprylthio-3-D-galactoside (IPTG) has been assessed by elec- 
trophoretic mobility shift analysis (Fig. 4 A). Recombinant 
NF-X1 binds to a radiolabeled,  double-stranded oligonucle- 
otide containing only the X1 box of the HLA-DRA gene 
promoter  and  seven nudeotides upstream  of the element 
(5'CCCTTCCCCTAGCAAGAGATG3'). The shift is abol- 
ished by adding 100-fold excess unlabeled competitor oligo- 
nucleotides containing the analogous regions of the other 
human class II MHC gene promoters: HLA-DRB, -DPA, 
-DPB,  -DQA, and -DQB. Addition of 100-fold excess unla- 
beled competitor oligonucleotide representing  other elements 
in the HLA-DRA promoter (the Y-box and the S-box) or 
elements found in other promoters (the SP1 motif and the 
PRDII element of the human IFN-3 gene promoter) does 
not influence the interaction of NF-X1 with its cognate rec- 
ognition sequence. These data indicate that NF-X1 interacts 
sequence specifically with all human class II MHC X1 boxes. 
Initial  Deliniation  of  the  DNA-binding  Domain  of NF- 
X1.  Using the strategy of Keller and Maniatis (43), an ini- 
tial definition of the NF-X1 DNA-binding domain has been 
accomplished (Fig. 4 B). Truncated forms of  the NF-X1 cDNA 
were created by PCR and ligated into EcoRI-cleaved,  phos- 
phatased )~gt11 DNA (44). The recombinant bacteriophage 
DNA was then packaged in high-efficiency  phage packaging 
extract (Stratagene).  The titer and frequency of recombina- 
tion of the recombinant phage was determined by plating 
on Y1088 Escherichia coli with IPTG and X-Gal included in 
Figure  3.  Genomic  organization  and transcription  of the NF-X1 gene. 
(A) Genomic  Southern blot probed with radiolabeled  NF-X1 eDNA in- 
sert. High molecular  weight  DNA was isolated  from murine splenocytes 
(lanes 1 and 2) and from  the human  B-lymphoma  cell line, clone-13 (lanes 
3 and 4). 20/~g DNA was digested  to completion  with EcoRI (lanes I 
and 3) or BamHI  (lanes  2 and 4), resolved  on a 1% agarose  gel, transferred 
to a hybridization  membrane, and probed with the radiolabeled  clone-16 
cDNA insert. The Southern  blot was subsequently  washed  at high strin- 
gency and subjected  to autoradiography.  The positions of DNA markers 
of Hindlll-digested  bacteriophage ~ DNA are indicated by arrows. (B) 
RT-PCR analysis  of total RNA isolated  from  Jijoye,  Jurkat, and RJ2.2.5. 
Lane  assignments  are: (1) Lambda  HindllI  plus  PhiX174/HaelII,  (2) posi- 
tive control, (3) negative  control (no template), (4) Jijoye template, (5) 
Jurkat template, and (6) RJ.2.2.5 template. (C) RNase protection  analysis 
of total RNA isolated  from  class II MHC-positive  and -negative  cell  lines. 
The RNAs utilized in the lanes labeled HELA + INF were extracted 
from HeLa  cells incubated for 24 h with 250 U/ml IFN-"/. 
1768  Identification  and Characterization of Human NF-X1 Figure  4.  NF-X1  is a sequence-specific  Xl-box binding protein that requires its cysteine-rich domain for DNA binding. (A) Electrophoretic mobility 
shift analysis of recombinant NF-X1. Recombinant NF-X1 forms a specific  complex with the double-stranded, DRA X1 box oligonucleotide (5'CCC- 
TTCCCCTAGCAAGAGATG3') which is competed for by 100-fold excess cold, double-stranded oligonucleotides containing the analogous regions 
from the HLA-DRB,  -DPA, -DPB, -DQA, and -DQB promoters but not by HLA-DRA Y-box (5'AAATATTTTTCTGATTGGCCAAAGAGT3'), 
S-box (5'TGTGTCCTGGACCCTTTGCAAGA3'), SP1 (5'ATTCGATCGGGGCGGGGCGAGC3') or the IFN-/3 gene-positive regulatory domain II 
(PRDII) element (5'GTGGGAAATTCCGTGGGAAATTCCG3'). (/3) Truncated forms of the NF-X1 cDNA were generated using the indicated restric- 
tion endonucleases, inserted into the pRSET series of bacterial expression vectors as described, and subsequently subcloned into the •gt11  bacteriophage 
and LNCX mammalian expression vectors. The ability of  each subclone to generate the expected polypeptide was assessed  by in vitro transcription/trans- 
lation of linearized templates and analysis of translation products on SDS/polyacrylamide  gels (data not shown). The relative positions of each fragment 
relative to the ORF are indicated. (C) In situ binding of induced fusion proteins encoded by ;kgt11 bacteriophage clones harboring the truncated NF-X1 
polypeptides shown in B.  After infection and induction,  filters were processed as indicated (29, 44). Recombinant NF-X1 fusion proteins encoded 
by Xgt11 phages D  and E retain Xl-box binding activity. 
the plates. Several recombinant plaques were isolated for each 
construction  and dideoxy sequence analysis of miniprepara- 
tions of phage DNA was performed to identify bacteriophage 
particles harboring the NF-X1 truncations in frame with the 
NH2-terminal portion of ~-galactosidase.  These phages were 
then plated on Y1090 bacteria, and the various truncated NF- 
X1  fusion proteins induced  and  assessed for their  ability to 
bind radiolabeled DRA-X1  box oligonucleotides  using the 
filter binding assay. The data presented in Fig. 4 C  show that 
the entire cysteine-rich region spanning amino acids 420-900 
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Figure  5.  NF-X1  encodes a transcriptional repressor of 
HLA-DRA  gene  expression.  (A)  Map  of the  eukaryotic 
retroviral expression vector-LNCX indicating the neomycin 
resistance gene for selection of stable transformants, the po- 
tent cytomegalovirus promoter, the multiple cloning site for 
insertion of NF-X1 cDNA and indicated subffagments, and 
the retroviral LTRs. (/3) Histograms showing the CAT ac- 
tivity produced in the class II MHC-positive cell line Raji 
and the class If-inducible cell line HeLa after cotransfection 
with the HLA-DRA  promoter reporter construct DRA- 
300CAT and increasing amounts of the LNCX expression 
vectors containing the NF-X1 cDNA in either the sense or 
antisense orientations. CAT activities are normalized to a 
cotransfected HGH expression vector as described (8). (C) 
Transcriptional repression requires the DNA-binding domain 
of NF-X1. Histograms showing CAT activity in Raji cells 
after cotransfection  with DRA300CAT and expression  vectors 
containing the previously described subfragments of the NF- 
X1  cDNA.  Only the LNCX.D  and LNCX.E  expression 
vectors mediate transcriptional repression from the DRA 
promoter. 
is necessary  and  sufficient  to mediate  interaction  with  the 
HLA-DRA  X1  box. 
NF-X1 Encodes a Repressor of HLA-DRA Transcription  and 
Requires the Cysteine-rich DNA-binding Domain  for Regulatory 
Function.  The regulatory  function  and effector  domain(s) 
of NF-X1  have been investigated  using mammalian expres- 
sion vectors encoding  the wild-type  and six truncated  NF- 
X1 polypeptides.  The six truncated NF-X1  forms described 
in Fig.  4 B  were generated by first subcloning  the indicated 
NF-X1  restriction  fragments  in  frame  with  the  NHz- 
terminal peptide  of the ptLSET,  A,B,C  series of expression 
vectors (Invitrogen)  to provide an NH2-terminal  methionine 
residue to each NF-X1  subfragment.  The resulting "expres- 
sion cassettes"  were then subcloned utilizing PCR methods 
into the retroviral vector pLNCX  (Fig.  5 A)  to generate a 
series  of mammalian  expression  vectors  for  cotransfection 
studies in mammalian cells (45). Each expression cassette was 
tested for its ability to direct the synthesis of the desired NF- 
X1 polypeptide by in vitro transcription and translation from 
linearized ptLSET derivatives (data not shown). The regula- 
tory function of NF-X1 has been assessed by cotransfection 
experiments where mammalian expression vectors encoding 
the wild-type and truncation derivatives of NF-X1 have been 
cotransfected  with  the  HLA-DRA  reporter  construct 
DRA300CAT into a series of class II-positive, class II-nega- 
tive, and IFN-'y-inducible  cell lines (46).  Wild-type NF-X1 
has been found to encode a potent repressor of HLA-DtLA 
transcription  in the class  lI-positive cell Raft (Fig.  5 B). It 
also represses DRA  transcription in IFN-'y-treated HeLa cells, 
but has no effect on DILA transcription  in untreated HeLa 
1770  Identification and Characterization of Human NF-X1 Figure  6.  NFX.1  RNA is overexpressed  late  after  in- 
cubation with IFN-~' and this coincides  with reduction 
in HLA-DRA  mRNA. HeLa  cells were incubated  with 
250 U/ml rlFN-3'  for the indicated  number  of hours be- 
fore isolation  of total RNA. 20/zg of total RNA from 
each sample was resolved  by electrophoresis through a 
formaldehyde  agarose gel and was transfered to a Gene 
Screen hybridization  membrane  by capillary  transfer. A 
photograph of  the  ethidium bromide stained gel  is 
presented to show  that equivalent  amounts  of  RNA were 
loaded for each sample. The same membrane was then 
probed with either  a DRA- or NFX.l-specific  radiolabeled 
probe, and the autoradiographs  are presented. The DRA 
gene is strongly  induced  by IFN-'), and the level of  DRA 
transcript increases  to a maximal  level  24 h postinduction. 
The level of DRA transcript is significantly  reduced at 
48 h after  induction.  The NFX.1 gene  is expressed  at very 
low levels as shown in Fig. 3 B, but is overexpressed  at 
48 h after induction. 
cells and the class II-negative T cell lineJurkat (Fig. 5 B and 
data not shown). Overexpression of NF-X1 has no effect on 
transcription from reporter constructs that lack the X1 binding 
site such as a c-36s reporter construct, FC4, and RSVCAT 
(data not shown). Using the expression vectors encoding trun- 
cated NF-X1 forms, the cysteine-rich DNA-binding domain 
has been shown to be necessary and sufficient to mediate this 
transcriptional repression (Fig.  5 C). NF-X1 forms lacking 
significant regions of the DNA-binding domain cannot re- 
press  HLA-DRA transcription. 
The NFX.1  mRNA Is Markedly Induced Late after Incuba- 
tion with IFN-  7 and this Coincides with Transcriptional Attenua- 
tion of the HLA-DRA  Gene.  Since artificial overexpression 
of the NFX.1 mRNA from retroviral constructs could re- 
press transcription from the HLA-DRA promoter, a careful 
kinetic analysis of NFX.1 mRNA expression  at several time 
points after incubation with IFN-3' was performed (Fig. 6). 
As is shown in Fig. 3/3, NFX.1 mKNA expression is difficult 
to detect in RNA derived from uninduced HeLa cells, and 
from HeLa cells incubated for short periods of time with 
100-200  U/ml rlFN-3'.  In contrast, the NFX.1  transcript 
is expressed at high levels in RNA derived from HeLa cells 
incubated for 48 h in the same concentration of IFN-3'. This 
overexpression  of NFX.1 mRNA coincides with a marked 
reduction in the steady state level of HLA-DRA transcript. 
The level of DRA transcript increases during the first 24 h 
of incubation with IFN-y and decreases significantly  by 48 h 
after induction (Fig.  6 and our unpublished data). In view 
of the inhibitory effect of NFX.1 overexpression  on HLA- 
DRA transcription (Fig. 5), these kinetic data strongly sug- 
gest that the NFX.1 protein functions in the postinduction 
turnoff of the HLA-DKA gene late after induction with 
IFN-'u 
Discussion 
A newly identified, cysteine-rich polypeptide which interacts 
sequence specifically with the conserved X1 box regulatory 
element found in the proximal promoters of class II MHC 
genes was described,  and its complementary DNA molecu- 
larly  cloned.  The  cysteine-rich domain  contains  a  motif 
repeated  seven times, and this entire region is necessary and 
sufficient for both sequence-specific binding and effector func- 
tion. The motif  is related to but distinct from the previously 
described metal-binding protein families  LIM domain and 
RING finger.  Overexpression of this protein strongly and 
specifically represses the transcription of the HLA-DRA gene 
in the class II-positive cell line Raji, and inhibits induction 
of the gene in the inducible cell line HeLa by IFN-3,, strongly 
suggesting that the NF-X1 protein encodes a transcriptional 
repressor.  Additional evidence that NFX.1 is a biologically 
relevant repressor of HLA-DRA gene expression stems from 
the finding that the NFX.1 mRNA is markedly overexpressed 
late after induction of HeLa cells with IFN-y, and that this 
overexpression coincides with a reduction in the level of HLA- 
DRA transcript in these ceils. The identification of NF-X1 
indicates that the X1 element, like the Y-box, can bind factors 
that can either activate or repress class II MHC gene expression. 
A  series of elegant classical genetic studies by Latron et 
al. (5) have previously demonstrated multiple genetic loci that 
encode either activators or repressors  of class II MHC gene 
expression  (for reviews  see references  4,  5).  These studies 
predicted the existence  of two classes of genes termed alr-1 
and slr-1 that encode either activator(s)  or silencer(s) of class 
II MHC gene expression,  respectively.  The newly isolated 
cDNA, CIITA, located on human chromosome 16, appears 
to encode alr-I (27, 28). The slr-1 gene or genes were identified 
in cell fusion experiments where factors expressed in the class 
II-negative plasmacytoma cell line P3-U1 were shown to rap- 
idly and dominantly repress  class II MHC transcription in 
the human B cell line Raji. Since the conserved  X1 box of 
class II MHC genes plays a critical role in the transcriptional 
regulation of these genes, we are actively investigating whether 
NF-X1  is in fact the product of the slr-1  locus. 
In addition to studies that will probe the interaction of 
NF-X1 with other known class II MHC and general pro- 
moter binding proteins, particular emphasis  will be placed 
on studies  to (a)  elucidate how NF-X1  interacts sequence 
specifically  with the X1 element and (b) probe how the effector 
function of NF-X1 is regulated in vivo. Three general models 
1771  Song et al. of how transcriptional repressors act include: (a) direct com- 
petition for binding  to  a  shared cis-element;  (b)  silencing 
(position-independent repression); and (c) neutralization (di- 
rect interaction with an essential activator), (47-53). The mo- 
lecular cloning of NF-X1  should allow investigations into 
which mechanism is operating at the X1 box. With regard 
to regulation of effector function, two lines of investigation 
are required. First, a more extensive analysis of NF-X1 ex- 
pression is required to determine whether the NF-X1 gene 
product might  be overexpressed in  other cell  types or in 
response to  physiological stimuli  other  than  IFN-y.  The 
repressor of IFN-3 gene expression, PRDI-BF1, is an example 
of a transcriptional repressor that binds to a positive regula- 
tory element and is regulated by overexpression after the IFN-3 
gene has been induced (54, 55). This protein is therefore in- 
volved in  the  postinduction  turn-off this  gene  (56).  It is 
noteworthy that the class II MHC genes are also  subject to 
postinduction turn-off after activation with IFN-3' (9). The 
NFX.1 protein appears to have a similar role in HLA-DRA 
transcription that has been induced by IFN-y. The second 
avenue of investigation involves  the multiple sites of post- 
translational modification that may be involved in regulating 
effector function in other situations. 
This information should contribt'te to our understanding 
of how class II MHC genes are regulated and may provide 
an avenue to manipulate the expression of these genes in dis- 
ease states.  Specifically, retroviral vectors (such as those de- 
scribed in this work) that can specifically repress the expression 
of class II MHC molecules might be useful as antiinflamma- 
tory reagents.  These studies may also  provide insight into 
the general problem of how the relative influence of two pro- 
teins that bind to the same cis-element, but which have op- 
posing regulatory function, can be determined. 
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